The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity

[1]  Jörg Schwenk,et al.  DISTINCT , 2022, Proceedings of the 2022 ACM SIGSAC Conference on Computer and Communications Security.

[2]  E. Rickel,et al.  ICOSL+ plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist , 2020, Science Translational Medicine.

[3]  Sierra M. Barone,et al.  CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation , 2020, JCI insight.

[4]  C. Siao,et al.  Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy , 2020, Science Translational Medicine.

[5]  E. Fedorov,et al.  Mechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complex , 2020, PloS one.

[6]  M. Hellmann,et al.  Acquired Resistance to Immune Checkpoint Inhibitors. , 2020, Cancer cell.

[7]  M. Yousefi,et al.  Blockage of immune checkpoint molecules increases T‐cell priming potential of dendritic cell vaccine , 2020, Immunology.

[8]  G. Freeman,et al.  Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells during Chronic Infection. , 2019, Immunity.

[9]  G. Nabel,et al.  Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation , 2019, Nature Cancer.

[10]  Xiaozheng Xu,et al.  PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. , 2019, Immunity.

[11]  Alberto Mantovani,et al.  The Two Faces of Tumor-Associated Macrophages and Their Clinical Significance in Colorectal Cancer , 2019, Front. Immunol..

[12]  T. Okazaki,et al.  Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses , 2019, Science.

[13]  Xiao-shi Zhang,et al.  Low expression of CD80 predicts for poor prognosis in patients with gastric adenocarcinoma. , 2019, Future oncology.

[14]  E. Rickel,et al.  Novel Immunomodulatory Proteins Generated via Directed Evolution of Variant IgSF Domains , 2017, Frontiers in Immunology.

[15]  G. Freeman,et al.  Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.

[16]  E. Hui,et al.  Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells , 2018, Cell reports.

[17]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[18]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[19]  D. Sansom,et al.  CTLA-4: a moving target in immunotherapy. , 2018, Blood.

[20]  K. Flaherty,et al.  Mechanisms of resistance to immune checkpoint inhibitors , 2018, British Journal of Cancer.

[21]  G. Freeman,et al.  PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface , 2018, Cancer Immunology Research.

[22]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[23]  Dana Pe’er,et al.  Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade , 2017, Cell.

[24]  Ju Yeon Lee,et al.  Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab , 2017, Scientific Reports.

[25]  G. Gao,et al.  Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab , 2017, Protein & Cell.

[26]  Koichi Araki,et al.  Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent , 2016, Science.

[27]  Aiwu Zhou,et al.  Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade , 2017, Cell Discovery.

[28]  J. Wolchok,et al.  Combination immunotherapy: a road map , 2017, Journal of Immunotherapy for Cancer.

[29]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[30]  Ronald D. Vale,et al.  T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition , 2016, Science.

[31]  Matheus C. Bürger,et al.  Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy , 2016, Nature.

[32]  P. Brun,et al.  CD80 down-regulation is associated to aberrant DNA methylation in non-inflammatory colon carcinogenesis , 2016, BMC Cancer.

[33]  Andrew D. Rouillard,et al.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..

[34]  Hai Hu,et al.  The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer , 2016, Tumor Biology.

[35]  K. Zak,et al.  Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. , 2015, Structure.

[36]  R. Thorpe,et al.  Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials — Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm , 2015, Journal of immunological methods.

[37]  S. Ostrand-Rosenberg,et al.  A Soluble Form of CD80 Enhances Antitumor Immunity by Neutralizing Programmed Death Ligand-1 and Simultaneously Providing Costimulation , 2014, Cancer Immunology Research.

[38]  C. Thompson,et al.  At the Bench: Preclinical rationale for CTLA‐4 and PD‐1 blockade as cancer immunotherapy , 2013, Journal of leukocyte biology.

[39]  Michael J. Davis,et al.  Macrophage M1/M2 Polarization Dynamically Adapts to Changes in Cytokine Microenvironments in Cryptococcus neoformans Infection , 2013, mBio.

[40]  Edward Y. Chen,et al.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.

[41]  A. Korman,et al.  Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells , 2013, Cancer Immunology Research.

[42]  R. Thorpe,et al.  After TGN1412: Recent developments in cytokine release assays , 2012, Journal of immunotoxicology.

[43]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[44]  N. Pannu,et al.  REFMAC5 for the refinement of macromolecular crystal structures , 2011, Acta crystallographica. Section D, Biological crystallography.

[45]  O. Majdic,et al.  T cell stimulator cells, an efficient and versatile cellular system to assess the role of costimulatory ligands in the activation of human T cells , 2010, Journal of immunological methods.

[46]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[47]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[48]  Alexei Vagin,et al.  Molecular replacement with MOLREP. , 2010, Acta crystallographica. Section D, Biological crystallography.

[49]  G. Freeman,et al.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.

[50]  D. Stuart,et al.  Crystal structure of a soluble CD28-Fab complex , 2005, Nature Immunology.

[51]  S. Almo,et al.  Structural mechanisms of costimulation , 2002, Nature Immunology.

[52]  P. Parren,et al.  Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1 , 2001, Journal of Virology.

[53]  Yan Zhang,et al.  Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses , 2001, Nature.

[54]  D I Stuart,et al.  Structure and dimerization of a soluble form of B7-1. , 2000, Immunity.

[55]  M. Izquierdo,et al.  Use of the 2A sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy , 1999, Gene Therapy.

[56]  D. Trono,et al.  A Third-Generation Lentivirus Vector with a Conditional Packaging System , 1998, Journal of Virology.

[57]  R. Karr,et al.  Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2). , 1996, Journal of immunology.

[58]  M. Hurle,et al.  Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4 , 1995, The Journal of experimental medicine.

[59]  P. Linsley,et al.  Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1 , 1994, The Journal of experimental medicine.

[60]  P. V. von Hippel,et al.  Calculation of protein extinction coefficients from amino acid sequence data. , 1989, Analytical biochemistry.